225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Investing in Malaysia's largest clinic operator to expand the healthcare business
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
ORACEA is a trademark of Galderma Holdings, S.A.
Subscribe To Our Newsletter & Stay Updated
